The association of antibodies to cardiolipin, β2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus

Scandinavian Journal of Rheumatology

Volumn 33, Issue 4, 2004, Pages 246-252

  Koskenmies, S ^a   Vaarala, O ^a   Widen, E ^a   Kere, J ^b   Palosuo, T ^a   Julkunen, H ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PEIJAS HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID BINDING PROTEIN; PROTHROMBIN;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL DISEASE; FEMALE; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 4444273530     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740410005386     Document Type: Article

References (51)

1. Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993;32:568-73.
2. Petri M. Thrombosis in systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1995;25:69-73.
3. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphosholipid antibodies. Adv Immunol 1991;49:193-280.
4. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999;93:2149-57.
5. Khamastha MA, Cuadrado MJ, Mujic F, Taub N, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;332:993-7.
6. Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid antibodies. Clin Rheum Dis 1985;11:591-601.
7. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Haematol Pathol 1988;2:121-43.
8. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
9. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Scienc USA 1990;87:4120-4.
10. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-32.
11. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-906.
12. Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606-7.
13. Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Antiprothrombin antibodies: assay conditions and clinical associations in the antiphospholipid syndrome. Br J Haematol 2001;113:544-9.
14. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherosclerosis. J Clin Invest 1991;88:1785-92.
15. Ames PR. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying 'membrane stress syndrome' hypothesis. Lupus 1994;3: 371-7.
16. Witztum JL, Horkko S. The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies. Ann New York Acad Sci 1997;811:88-96.
17. Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Enholm C, et al. Antibodies against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-9.
18. Amengual O, Atsumi T, Khamastha MA, Tinahones F, Hughes GR. Autoantibodies against oxidized low-density lipoprotein in antiphosholipid syndrome. Br J Rheumatol 1997;36:964-8.
19. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
20. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-9.
21. Cevallos R, Darnige L, Arvieux J, Veyssier P, Gruel Y. Antiphospholipid and β2 glycoprotein-I antibodies in monozygotic twin sisters. J Rheumatol 1994;21:70-1.
22. Wilson WA. Family studies and the major histocompatibility complex. In: Khamastha MA, editors. Hughes syndrome. London: Springer-Verlag; 2000:348-57.
23. Koskenmies S, Widen E, Kere J, Julkunen H. Familial systemic lupus erythematosus in Finland. J Rheumatol 2001;28:758-60.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
25. Vaarala O. Binding profiles of anticardiolipin antibodies in sera from patients with SLE and infectious diseases. J Autoimmun 1991;4:819-30.
26. Palosuo T, Virtamo J, Haukka J, Taylor PR, Aho K, Puurunen M, Vaarala O. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - a nested case-control study. Thromb Haemost 1997;78:1178-8.
27. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis. Lupus 1997;6:467-73.
28. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
29. Rand JH. The antiphospholipid syndrome. Annu Rev Med 2003;54:409-24.
30. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza L. IgA anticardiolipin and anti beta2 - glycoprotein I are the most prevalent isotypes in African patients with systemic lupus erythematosus. Am J Med Sci 1999;318: 55-65.
31. Lopez LR, Santos ME, Espinoza LR, La Rosa FG. Clinical significance of IgA versus IgM anticardiolipin antibodies in patients with SLE. Am J Clin Pathol 1992;98:449-54.
32. Molina JF, Gutierrez-Urena S, Molina J, Uribe O, Richards S, De Ceulaer C, et al. Validity of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997; 24:291-6.
33. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986;41:8-15.
34. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989;68:353-65.
35. Jouhikainen T, Julkunen H, Vaarala O, Leirisalo-Repo M, Stephansson E. Vahtera E, et al. Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: comparison of three lupus anticoagulant assays and anticardiolipin ELISA in 188 patients. Blood Coagul Fibrinolysis 1992;3:407-14.
36. Gharavi AE, Harris EN, Asherson R, Hughes GRV. Anticardiolipin antibody isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
37. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on premininary clasification criteria for definite antiphosholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
38. Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 2001;7:241-58.
39. Horbach DA, v Oort E, Donders RCJM, Derksen RHWM, deGroot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemost 1996;76: 916-24.
40. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glykoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008-14.
41. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114:647-54.
42. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;15:721-4.
43. Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, et al. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997;24:1710-5.
44. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
45. Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996;75:456-9.
46. Derksen RH, Hasselaar P, Blokzijl L, Gmelig Meyling FH, de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988;47:364-71.
47. Hayem G, Nicaise-Roland P, Palazzo E, de Bandt M, Tubach F, Weber M, et al. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001;10:346-51.
48. Romero FI, Amengual O, Atsumi T, Khamashta MA, Tinahones FJ, Hughes GR. Arterial disease in lupus and secondary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998;37:883-8.
49. Cuadrado MJ, Tinahones F, Camps MT, de Ramon E, Gomez-Zumaquero JM, Mujic F, et al. Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low- density-lipoprotein antibodies in antiphospholipid syndrome. Q J Med 1998;91:619-26.
50. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 2001;30:436-43.
51. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999;74: 275-84.